A great place to start your early clinical development is with a first-in-human (FIH) study conducted by Altasciences. Our recent experience includes more than 200 FIH studies for both small molecules and biologics.

Altasciences can help get an early signal of proof of concept for your new molecule or formulation, given our years of experience in capturing objective and subjective measures, from biomarkers to assessment of signs and symptoms.

With more than 10,000 simulated drives, we have extensive experience designing and conducting driving simulation studies to establish extent and duration of drug-related impairment, or to demonstrate an improvement in driving ability after pharmaceutical treatment.

Studies looking at human abuse potential and abuse-deterrent formulations require specialized pharmacies, highly trained staff, robust patient databases, and the operational skill to retain participants.

Altasciences has designed, conducted, analyzed, and reported on more than 1,600 bioavailability (BA) and bioequivalence (BE) studies for more than 1,200 products or combinations.

Drug-drug and drug-alcohol interaction studies are important steps in finalizing the clinical pharmacology details of your product label. Trust your DDI and drug-alcohol studies to a CRO that has been designing and conducting them for decades.

We can rapidly recruit a broad range of special population participants for PK studies, using a combination of our existing database and participant outreach.

We have been designing and conducting QT studies since the FDA E14 guidance was finalized. Altasciences has experience in both early cardiac safety assessment and thorough QT prolongation studies.

Renal and hepatic impaired studies are often part of the last set of clinical pharmacology studies needed for regulatory approval. Plan ahead with Altasciences to keep you moving seamlessly toward approval.

Altasciences has the experience and affiliated facilities to incorporate imaging into most clinical pharmacology studies.

With decades of experience in testing of biologics or biosimilar products, we offer the preclinical, clinical, and bioanalytical expertise you need to move your large molecule programs forward. In fact, more than 40% of our current preclinical and clinical studies are conducted on biologics.

From conducting the world’s first safety and tolerability testing of a novel combustible cannabis formulation, to testing synthetic cannabinoids or products for the recreational market, Altasciences is a world leader in cannabis preclinical and clinical testing.

Safety and abuse potential testing of cannabis and new tobacco products (such as electronic nicotine delivery or heat-not-burn systems) is becoming more complex. You can rely on Altasciences’ experience — a CRO that understands clinical design and requirements for conducting smoking/vaping studies.